A Real‐World Study of CAR‐T Hematological Adverse Events Based on FAERS Database.

Chimeric antigen receptor T‐cell therapy (CAR‐T) is an emerging therapy for malignancies, including refractory B‐cell lymphoma, follicular lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Postmarketing monitoring is essential to ensure the rational administration of CAR‐T because of its...

Full description

Bibliographic Details

Published in:	Journal of Clinical Pharmacy & Therapeutics Vol. 2025; pp. 1 - 12
Main Authors:	Gao, Xiaoyue, Hu, Fangyuan, Zhai, Yinghong, Yuan, Lei, Li, He, Ye, Xiaofei, Wang, Zhuo, Imran, Ali
Format:	research tables/charts Journal Article
Published:	Wiley-Blackwell 11/23/2025
Online Access:	View this record in EBSCOhost